New drug combination for the second treatment of some HR-positive advanced breast cancers
Full article:

The FDA approved Truqap plus Faslodex for the treatment of metastatic hormone receptor-positive (HR-positive), HER2-negative breast cancer that returned or worsened after treatment with hormone therapy. The approval is for treating cancers in people whose tumors had a mutation in one of three genes. For people with one of these mutations, Truqap improved the time until their cancer came back or got worse.  (Posted 2/9/24)

Este artículo está disponible en español.

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following are studies looking at treatment for people with metastatic HER2-positive breast cancer.  

Other clinical trials for people with breast cancer can be found here.


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.